US · SPRO
Spero Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- sperotherapeutics.com
Price · as of 2024-12-31
$2.48
Market cap 122.26M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $31.48 | +1,169.35% |
| Intrinsic Value(DCF) | $0.31 | -87.5% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $54.98 | +2,116.94% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $12.00 | $57.65 | $1,532,376.82 | $0.00 | $0.00 |
| 2018 | $11.75 | $32.58 | $4.25 | $0.00 | $0.00 |
| 2019 | $9.18 | $43.77 | $986,154.99 | $0.00 | $0.00 |
| 2020 | $16.74 | $20.93 | $2.54 | $0.00 | $134.12 |
| 2021 | $8.36 | $35.36 | $0.00 | $0.00 | $162.56 |
| 2022 | $1.48 | $225.78 | $794.80 | $0.00 | $0.00 |
| 2023 | $1.66 | $47.44 | $15,942.75 | $4.19 | $50.54 |
| 2024 | $0.78 | $31.48 | $59.03 | $0.00 | $54.98 |
AI valuation
Our deep-learning model estimates Spero Therapeutics, Inc.'s (SPRO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $31.48
- Current price
- $2.48
- AI upside
- +1,169.35%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.31
-87.5% upside
Graham-Dodd
—
— upside
Graham Formula
$54.98
+2,116.94% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SPRO | Spero Therapeutics, Inc. | $2.48 | 122.26M | +1,169% | -87% | — | +2,117% | -0.61 | 0.91 | 0.88 | 0.09 | — | 0.91 | -101.67% | -152.91% | -142.91% | -89.62% | -436.22% | -46.81% | 0.09 | — | 2.19 | 2.15 | 0.67 | -39535.00% | -5377.00% | -2895.00% | -55.69% | -0.48 | -139.40% | 0.00% | 0.00% | 0.00% | 0.09 | 0.28 | -0.14 | -6.55 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| ACTU | Actuate Therapeutics Inc | $3.74 | 86.93M | — | — | — | — | -4.97 | 1301.78 | — | -5.05 | -5.09 | 1301.78 | 0.00% | — | — | 54.83% | 45.28% | -443.16% | 0.00 | 1344.27 | 1.05 | 0.98 | 0.34 | 9758.00% | — | 101.00% | -16.10% | -2.48 | 39.31% | 0.00% | 0.00% | 4.19% | -5.05 | -5.81 | — | -19.92 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| CRBP | Corbus Pharmaceuticals Ho… | $8.57 | 107.43M | — | — | — | — | -1.84 | 0.52 | — | 1.90 | — | 0.52 | 0.00% | — | — | -59.34% | 944.11% | -43.67% | 0.02 | -26.03 | 12.94 | 12.61 | 0.37 | -6431.00% | — | 1577.00% | -56.39% | -3.54 | 809.88% | 0.00% | 0.00% | 28.50% | 1.47 | 1.72 | — | -0.92 |
| HURA | TuHURA Biosciences, Inc. | $1.67 | 94.32M | — | — | — | — | -1.80 | 2.67 | — | -1.52 | — | 2.67 | 0.00% | — | — | -332.67% | 4773.62% | -178.25% | 0.01 | -4.26 | 3.68 | 2.42 | 0.71 | -8925.00% | — | 2291.00% | -37.91% | -2.76 | 3999.15% | 0.00% | 0.00% | 28.55% | -1.50 | -1.80 | — | -5.49 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| MCRB | Seres Therapeutics, Inc. | $8.74 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| VTGN | VistaGen Therapeutics, In… | $0.59 | 19.2M | +3,740% | +110% | — | +12,444% | -1.41 | 1.03 | 149.14 | 0.12 | -14.28 | 1.03 | 100.00% | -11517.08% | -10579.84% | -55.68% | 986.92% | -49.44% | 0.02 | — | 6.51 | 6.38 | 1.19 | 987.00% | -5432.00% | 6344.00% | -58.34% | -3.34 | 745.62% | 0.00% | 0.00% | 0.00% | 0.12 | 0.15 | -13.36 | -4.85 |
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- CEO
- Esther Rajavelu
- Employees
- 32
- Beta
- 1.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.31 ÷ $2.48) − 1 = -87.5% (DCF, example).